Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Sets Out Plan to Ease Export Ban for Plasma Fraction Products
September 7, 2017
- MHLW Working Group to Draw Up Elderly Polypharmacy Guidelines in 2 Stages
September 4, 2017
- Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
September 4, 2017
- Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law
September 1, 2017
- MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
- MHLW Panels Eye Cognitive Behavioral Therapy Approach for Post-HPV Vaccine Symptoms
August 29, 2017
- New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost
August 29, 2017
- MHLW Predicts 4% Reduction in Flu Vaccine Production in FY2017, Will Take Steps to Prevent Shortage
August 29, 2017
- MHLW OKs Add’l Indications for Revolade, Actemra and More
August 28, 2017
- Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
- MHLW Health Policy Bureau to Initiate a New Project to Increase Understanding of Biosimilars; FY2018 Budget Request
August 28, 2017
- MHLW Pharmaceutical Safety Bureau Seeks 10.3 Billion Yen in FY2018 Budget; Includes Funding for 6 Add’l Personnel at PMDA
August 28, 2017
- MHLW Working Group to Kick Off Discussions on Guidelines to Address Elderly Polypharmacy
August 25, 2017
- MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
- MHLW Council Recommends Public Knowledge-Based Applications for 2 Products Including Velcade
August 25, 2017
- MHLW Presents Steps Responding to Chuikyo Reps’ Concerns for “Willing-to-Pay Cost” Survey
August 24, 2017
- Chuikyo OKs MHLW’s Discussion Timeline on CEA, 3 Subcommittees to Hold Joint Debates
August 24, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…